TearLab slides after reporting wider-than-expected loss

Shares of TearLab (TEAR) sink 9% AH as the company reports a Q2 loss that is three times wider than analysts expected.

Results were impacted to the tune of -$0.26 by "the revaluation of warrants issued in June 2011 and annual options that were granted and fully vested in Q2."

It's worth noting that while revenues rose 392% Y/Y, cost of good sold jumped 524% from Q2 2012. Sales and marketing expenses rose 268%. (PR)

Total Osmolarity systems booked for Q2: 569.

Cash and equivalents as of June 30 of $7.2M. This obviously doesn't include the $37.5M TEAR raised in a public offering on July 25.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs